智通财经APP获悉,香港联交所最新资料显示,9月4日,华康生物医学(08622)股东将股票存入中昊证券,存仓市值4950.83万港元,占比24.13%。
8月15日,华康生物医学发布截至2025年6月30日止六个月业绩,收入1232.9万元(人民币,下同),同比增长3.4%;净亏损236.9万元,同比扩大33.2%;每股基本亏损0.47仙。收益增加主要由于报告期间,集团男性不育体外诊断试剂及寄生虫系列检测试剂的销售增加。
智通财经APP获悉,香港联交所最新资料显示,9月4日,华康生物医学(08622)股东将股票存入中昊证券,存仓市值4950.83万港元,占比24.13%。
8月15日,华康生物医学发布截至2025年6月30日止六个月业绩,收入1232.9万元(人民币,下同),同比增长3.4%;净亏损236.9万元,同比扩大33.2%;每股基本亏损0.47仙。收益增加主要由于报告期间,集团男性不育体外诊断试剂及寄生虫系列检测试剂的销售增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.